Browse Category

Biotech Stocks News 25 November 2025 - 9 December 2025

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference (RNAi) specialist climbed to a new 52‑week high near $69 per share after the company announced
Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Published: December 8, 2025 Dyne Therapeutics (NASDAQ: DYN) is back on biotech investors’ radar after releasing highly anticipated topline data from its Phase 1/2 DELIVER trial in Duchenne muscular dystrophy (DMD), sending the stock sharply higher on Monday. By mid‑afternoon
Top Pre‑Market Gainers Today (December 8, 2025): Confluent, Carvana and Biotech Names Lead Fed‑Week Rally

Top Pre‑Market Gainers Today (December 8, 2025): Confluent, Carvana and Biotech Names Lead Fed‑Week Rally

U.S. stock futures are edging higher on Monday, December 8, 2025, as traders head into a pivotal Federal Reserve meeting widely expected to deliver this year’s final rate cut. Nasdaq 100 futures are up around a quarter of a percent,
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) extended its remarkable 2025 rally on Friday, December 5, with shares surging almost 40% intraday after the company reported a double dose of good news: a pivotal epilepsy trial stopped early for efficacy and
Sensei Biotherapeutics (SNSE) Stock: Wild Volatility After Solnerstotug Shutdown and Strategic Review – Price, News and 2025–2026 Forecast

Sensei Biotherapeutics (SNSE) Stock: Wild Volatility After Solnerstotug Shutdown and Strategic Review – Price, News and 2025–2026 Forecast

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) has suddenly landed back on traders’ radars. After months of drifting as a tiny, cash‑rich micro‑cap biotech, the stock exploded higher at the start of December 2025 – just weeks after the company killed its
Capricor Therapeutics (CAPR) Soars on Positive Phase 3 HOPE‑3 Results: Latest Stock News, Analyst Targets and 2025 Outlook

Capricor Therapeutics (CAPR) Soars on Positive Phase 3 HOPE‑3 Results: Latest Stock News, Analyst Targets and 2025 Outlook

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is back in the spotlight on December 3, 2025, after announcing positive topline results from its pivotal Phase 3 HOPE‑3 trial of deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD). The news has reignited hopes for
Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

On December 2, 2025, Polyrizon Ltd. (NASDAQ: PLRZ) went from obscure micro-cap to center stage as its stock exploded more than 130% in a single session after the company announced a key manufacturing milestone for its flagship nasal spray platform.
PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus

PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus

As traders log in on Tuesday, November 25, 2025, Plus Therapeutics (NASDAQ:PSTV) is back on the radar thanks to a cluster of late‑November catalysts: an FDA Type B meeting for lead radiotherapeutic REYOBIQ™, a fresh 180‑day Nasdaq bid‑price extension, and
Go toTop